MA52795A - Dérivé de carbamoylpyridone polycyclique - Google Patents

Dérivé de carbamoylpyridone polycyclique

Info

Publication number: MA52795A
Authority: MA; Morocco
Prior art keywords: polycyclic carbamoylpyridone; carbamoylpyridone derivative; derivative; polycyclic; carbamoylpyridone
Prior art date: 2018-05-31

Application number

MA052795A

Other languages

English (en)

Other versions

MA52795B1 (fr

Inventor

Yoshiyuki Taoda

Yuto UNOH

Original Assignee

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-31

Filing date

2019-05-30

Publication date

2021-04-14

2019-05-30 Application filed by Shionogi & Co filed Critical Shionogi & Co

2021-04-14 Publication of MA52795A publication Critical patent/MA52795A/fr

2024-09-30 Publication of MA52795B1 publication Critical patent/MA52795B1/fr

Links

OHEKQGOBJIKKIF-AWEZNQCLSA-N (12as)-n-[(4-fluorophenyl)methyl]-7-hydroxy-6,8-dioxo-3,4,12,12a-tetrahydro-2h-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide Chemical class C([C@@H]1OCCCN1C(=O)C1=C(C2=O)O)N1C=C2C(=O)NCC1=CC=C(F)C=C1 OHEKQGOBJIKKIF-AWEZNQCLSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

MA52795A 2018-05-31 2019-05-30 Dérivés de carbamoylpyridone polycycliques pour le traitement du vih MA52795B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2018104156		2018-05-31
PCT/JP2019/021446 WO2019230858A1 (fr)	2018-05-31	2019-05-30	Dérivé de carbamoylpyridone polycyclique
EP19810498.6A EP3805220B1 (fr)	2018-05-31	2019-05-30	Dérivés de carbamoylpyridone polycycliques pour le traitement du vih

Publications (2)

Publication Number	Publication Date
MA52795A true MA52795A (fr)	2021-04-14
MA52795B1 MA52795B1 (fr)	2024-09-30

Family

ID=68698918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA52795A MA52795B1 (fr)	2018-05-31	2019-05-30	Dérivés de carbamoylpyridone polycycliques pour le traitement du vih

Country Status (37)

Country	Link
US (3)	US11649236B2 (fr)
EP (2)	EP3805220B1 (fr)
JP (2)	JP7328962B2 (fr)
KR (2)	KR20250002769A (fr)
CN (2)	CN117327072A (fr)
AR (1)	AR115455A1 (fr)
AU (2)	AU2019277548B2 (fr)
BR (1)	BR112020024077A2 (fr)
CA (1)	CA3102063A1 (fr)
CL (1)	CL2020003002A1 (fr)
CO (1)	CO2020014294A2 (fr)
CR (2)	CR20230571A (fr)
DK (1)	DK3805220T3 (fr)
DO (1)	DOP2020000221A (fr)
EA (1)	EA202092921A1 (fr)
ES (1)	ES2984245T3 (fr)
FI (1)	FI3805220T3 (fr)
HR (1)	HRP20241221T1 (fr)
HU (1)	HUE068170T2 (fr)
IL (2)	IL313474A (fr)
LT (1)	LT3805220T (fr)
MA (1)	MA52795B1 (fr)
MD (1)	MD3805220T2 (fr)
MX (2)	MX2020012176A (fr)
MY (1)	MY198568A (fr)
NZ (1)	NZ771017A (fr)
PE (2)	PE20251594A1 (fr)
PH (1)	PH12020552000A1 (fr)
PL (1)	PL3805220T3 (fr)
PT (1)	PT3805220T (fr)
RS (1)	RS65891B1 (fr)
SG (1)	SG11202011382PA (fr)
SI (1)	SI3805220T1 (fr)
SM (1)	SMT202400330T1 (fr)
UA (1)	UA129229C2 (fr)
WO (1)	WO2019230858A1 (fr)
ZA (1)	ZA202007567B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN119462659A (zh)	2019-03-22	2025-02-18	吉利德科学公司	桥连三环氨基甲酰基吡啶酮化合物及其药学用途
US12577241B2 (en)	2019-11-28	2026-03-17	Shionogi & Co., Ltd.	Polycyclic pyridopyrazine derivative
JPWO2021107066A1 (fr) *	2019-11-28	2021-06-03
PE20221569A1 (es)	2020-02-24	2022-10-06	Gilead Sciences Inc	Compuestos tetraciclicos para el tratamiento de infecciones por vih
WO2021233302A1 (fr) *	2020-05-21	2021-11-25	南京明德新药研发有限公司	Dérivés cycliques fusionnés et leur utilisation en pharmacie
EP4188379B1 (fr) *	2020-07-27	2026-02-25	Merck Sharp & Dohme LLC	Inhibiteurs polycycliques de l'endonucléase dépendants de cap pour le traitement ou la prévention de la grippe
WO2022072520A1 (fr)	2020-09-30	2022-04-07	Gilead Sciences, Inc.	Composés de carbamoylpyridone tricyclique pontés et leurs utilisations
LT4196479T (lt) *	2021-01-19	2023-12-11	Gilead Sciences, Inc.	Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
CN117751118A (zh) *	2021-07-30	2024-03-22	吉斯凯(苏州)制药有限公司	大环吡啶酮类化合物及其应用
TW202446773A (zh)	2022-04-06	2024-12-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024061257A1 (fr) *	2022-09-20	2024-03-28	吉斯凯(苏州)制药有限公司	Composé cétone n-hétérocyclique polycyclique et son utilisation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003267098B2 (en)	2002-09-11	2008-11-20	Merck & Co., Inc.	Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
EP1578748B1 (fr)	2002-12-27	2010-09-15	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Tetrahydro-4h-pyrido[1,2-a]pyrimidines et composes connexes convenant comme inhibiteurs de l'integrase du vih
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2006088173A1 (fr)	2005-02-21	2006-08-24	Shionogi & Co., Ltd.	Dérivé de carbamoylpyridone bicyclique ayant une activité d'inhibition de la vih intégrase
US8129385B2 (en)	2005-04-28	2012-03-06	Shionogi & Co., Ltd.	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
CN101346376A (zh) *	2005-10-27	2009-01-14	盐野义制药株式会社	具有hiv整合酶抑制活性的多环性氨基甲酰基吡啶酮衍生物
EP1950212B1 (fr)	2005-10-27	2016-02-24	Shionogi Co., Ltd.	Dérivé de carbamoylpyridone polycyclique ayant une activité d'inhibition sur l'intégrase du vih
KR20120130185A (ko)	2010-02-26	2012-11-29	니뽄 다바코 산교 가부시키가이샤	１,３,４,８―테트라히드로―２Ｈ―피리도［１,２―ａ］피라진 유도체 및 그의 ＨＩＶ 인테그라제 저해제로서의 이용
US9216995B2 (en)	2010-04-12	2015-12-22	Shionogi & Co., Ltd.	Pyridone derivative having integrase inhibitory activity
US9200009B2 (en)	2011-10-12	2015-12-01	Shionogi & Co., Ltd.	Polycyclic pyridone derivative having integrase inhibitory activity
US9714243B2 (en)	2012-12-17	2017-07-25	Merck Sharp & Dohme Corp.	4-pyridinonetriazine derivatives as HIV integrase inhibitors
PL3608325T3 (pl)	2012-12-21	2022-11-07	Gilead Sciences, Inc.	Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
AU2013366981A1 (en)	2012-12-27	2015-06-18	Japan Tobacco Inc.	Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
EP3330272B1 (fr)	2013-05-17	2021-02-17	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés en tant qu'inhibiteurs de l'intégrase du vih
WO2014200880A1 (fr) *	2013-06-13	2014-12-18	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
NO2865735T3 (fr)	2013-07-12	2018-07-21
HUE037347T2 (hu)	2013-07-12	2018-08-28	Gilead Sciences Inc	Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
WO2015039348A1 (fr)	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
KR102102516B1 (ko)	2013-09-27	2020-04-20	머크 샤프 앤드 돔 코포레이션	Hiv 인테그라제 억제제로서 유용한 치환된 퀴놀리진 유도체
WO2015089847A1 (fr)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
WO2015199167A1 (fr)	2014-06-25	2015-12-30	日本たばこ産業株式会社	PROCÉDÉ POUR PRÉPARER UN DÉRIVÉ SUBSTITUÉ DE SPIROPYRIDO[1,2-a]PYRAZINE ET INTERMÉDIAIRE
EP3757105B1 (fr)	2014-08-22	2024-07-24	Shionogi & Co., Ltd.	Dérivé de pyridone polycyclique possédant une activité inhibitrice d'intégrase
WO2016090545A1 (fr)	2014-12-09	2016-06-16	Merck Sharp & Dohme Corp.	Composés hétérocycliques spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3229804B1 (fr)	2014-12-09	2020-05-06	Merck Sharp & Dohme Corp.	Composés hétérocycliques spirocycliques utiles comme inhibiteurs du vih
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016154527A1 (fr)	2015-03-26	2016-09-29	Merck Sharp & Dohme Corp.	Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih
ES2837383T3 (es)	2015-04-02	2021-06-30	Gilead Sciences Inc	Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
WO2016187788A1 (fr)	2015-05-25	2016-12-01	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
EP3377065B1 (fr)	2015-11-17	2022-05-18	Merck Sharp & Dohme Corp.	Dérivés de pyridotriazine spirocyclique utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017087257A1 (fr)	2015-11-17	2017-05-26	Merck Sharp & Dohme Corp.	Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017106071A1 (fr)	2015-12-15	2017-06-22	Merck Sharp & Dohme Corp.	Dérivés de quinolizine spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017113288A1 (fr)	2015-12-31	2017-07-06	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques condensés utiles en tant qu'inhibiteurs de l'intégrase du vih
JOP20190130A1 (ar)	2016-12-02	2019-06-02	Merck Sharp & Dohme	مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
EP3548031B1 (fr)	2016-12-02	2023-07-19	Merck Sharp & Dohme LLC	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3752144B1 (fr)	2018-02-15	2022-12-28	Merck Sharp & Dohme LLC	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
JP2021522254A (ja)	2018-04-27	2021-08-30	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
CN110526930B (zh)	2018-05-23	2022-06-03	莫云芬	抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
AU2019277547B2 (en)	2018-05-31	2024-10-10	Shionogi & Co., Ltd.	Polycyclic pyridone derivative
US11884683B2 (en)	2018-06-05	2024-01-30	Merck Sharp & Dohme Llc	Tricyclic heterocycle compounds useful as HIV integrase inhibitors
CN108957755B (zh)	2018-07-27	2021-04-30	京东方科技集团股份有限公司	一种显示组件及其控制方法、平视显示器及汽车
CN119462659A (zh)	2019-03-22	2025-02-18	吉利德科学公司	桥连三环氨基甲酰基吡啶酮化合物及其药学用途

2019
- 2019-05-30 PE PE2025000789A patent/PE20251594A1/es unknown
- 2019-05-30 CA CA3102063A patent/CA3102063A1/fr active Pending
- 2019-05-30 JP JP2020522577A patent/JP7328962B2/ja active Active
- 2019-05-30 WO PCT/JP2019/021446 patent/WO2019230858A1/fr not_active Ceased
- 2019-05-30 MY MYPI2020006045A patent/MY198568A/en unknown
- 2019-05-30 IL IL313474A patent/IL313474A/en unknown
- 2019-05-30 PT PT198104986T patent/PT3805220T/pt unknown
- 2019-05-30 PE PE2020001863A patent/PE20210477A1/es unknown
- 2019-05-30 HU HUE19810498A patent/HUE068170T2/hu unknown
- 2019-05-30 AU AU2019277548A patent/AU2019277548B2/en active Active
- 2019-05-30 KR KR1020247040377A patent/KR20250002769A/ko active Pending
- 2019-05-30 MX MX2020012176A patent/MX2020012176A/es unknown
- 2019-05-30 SM SM20240330T patent/SMT202400330T1/it unknown
- 2019-05-30 CN CN202311258763.1A patent/CN117327072A/zh active Pending
- 2019-05-30 LT LTEPPCT/JP2019/021446T patent/LT3805220T/lt unknown
- 2019-05-30 US US17/058,251 patent/US11649236B2/en active Active
- 2019-05-30 PL PL19810498.6T patent/PL3805220T3/pl unknown
- 2019-05-30 CR CR20230571A patent/CR20230571A/es unknown
- 2019-05-30 FI FIEP19810498.6T patent/FI3805220T3/fi active
- 2019-05-30 CR CR20200644A patent/CR20200644A/es unknown
- 2019-05-30 SG SG11202011382PA patent/SG11202011382PA/en unknown
- 2019-05-30 MD MDE20210334T patent/MD3805220T2/ro unknown
- 2019-05-30 DK DK19810498.6T patent/DK3805220T3/da active
- 2019-05-30 SI SI201930798T patent/SI3805220T1/sl unknown
- 2019-05-30 BR BR112020024077-0A patent/BR112020024077A2/pt active IP Right Grant
- 2019-05-30 UA UAA202008303A patent/UA129229C2/uk unknown
- 2019-05-30 EP EP19810498.6A patent/EP3805220B1/fr active Active
- 2019-05-30 NZ NZ771017A patent/NZ771017A/en unknown
- 2019-05-30 EP EP23192706.2A patent/EP4257137A3/fr active Pending
- 2019-05-30 HR HRP20241221TT patent/HRP20241221T1/hr unknown
- 2019-05-30 EA EA202092921A patent/EA202092921A1/ru unknown
- 2019-05-30 CN CN201980050399.5A patent/CN112513042B/zh active Active
- 2019-05-30 KR KR1020207037580A patent/KR102741390B1/ko active Active
- 2019-05-30 RS RS20240971A patent/RS65891B1/sr unknown
- 2019-05-30 MA MA52795A patent/MA52795B1/fr unknown
- 2019-05-30 AR ARP190101467A patent/AR115455A1/es unknown
- 2019-05-30 ES ES19810498T patent/ES2984245T3/es active Active
- 2019-05-30 IL IL279051A patent/IL279051B2/en unknown
2020
- 2020-11-13 MX MX2023010377A patent/MX2023010377A/es unknown
- 2020-11-18 CL CL2020003002A patent/CL2020003002A1/es unknown
- 2020-11-18 CO CONC2020/0014294A patent/CO2020014294A2/es unknown
- 2020-11-20 PH PH12020552000A patent/PH12020552000A1/en unknown
- 2020-11-27 DO DO2020000221A patent/DOP2020000221A/es unknown
- 2020-12-04 ZA ZA2020/07567A patent/ZA202007567B/en unknown
2023
- 2023-03-22 US US18/124,827 patent/US12139489B2/en active Active
- 2023-08-03 JP JP2023127333A patent/JP7679427B2/ja active Active
2024
- 2024-02-08 AU AU2024200783A patent/AU2024200783B2/en active Active
- 2024-06-26 US US18/755,191 patent/US20240352015A1/en active Pending

Also Published As

Publication number	Publication date
ES2984245T3 (es)	2024-10-29
IL279051B1 (en)	2024-09-01
EP3805220B1 (fr)	2024-07-31
EP4257137A2 (fr)	2023-10-11
PH12020552000A1 (en)	2021-09-27
SMT202400330T1 (it)	2024-09-16
JP7679427B2 (ja)	2025-05-19
BR112020024077A2 (pt)	2021-02-09
US11649236B2 (en)	2023-05-16
EP4257137A3 (fr)	2023-11-01
AU2019277548A1 (en)	2021-01-14
MD3805220T2 (ro)	2024-10-31
SI3805220T1 (sl)	2024-10-30
KR20210015922A (ko)	2021-02-10
CR20230571A (es)	2024-01-22
NZ771017A (en)	2026-01-30
MX2023010377A (es)	2023-09-12
HRP20241221T1 (hr)	2024-12-06
CN112513042A (zh)	2021-03-16
PE20251594A1 (es)	2025-06-16
ZA202007567B (en)	2022-04-28
MX2020012176A (es)	2021-01-29
CN117327072A (zh)	2024-01-02
JPWO2019230858A1 (ja)	2021-06-24
CA3102063A1 (fr)	2019-12-05
HUE068170T2 (hu)	2024-12-28
CR20200644A (es)	2021-02-05
CO2020014294A2 (es)	2020-12-21
AU2024200783B2 (en)	2026-03-26
EP3805220A4 (fr)	2022-01-05
WO2019230858A1 (fr)	2019-12-05
DOP2020000221A (es)	2021-03-15
RS65891B1 (sr)	2024-09-30
JP2023145723A (ja)	2023-10-11
IL313474A (en)	2024-08-01
KR102741390B1 (ko)	2024-12-10
AU2024200783A1 (en)	2024-02-29
US20230227454A1 (en)	2023-07-20
MA52795B1 (fr)	2024-09-30
PL3805220T3 (pl)	2024-11-04
CN112513042B (zh)	2023-09-29
KR20250002769A (ko)	2025-01-07
JP7328962B2 (ja)	2023-08-17
IL279051A (en)	2021-01-31
EP3805220A1 (fr)	2021-04-14
SG11202011382PA (en)	2020-12-30
PE20210477A1 (es)	2021-03-11
EA202092921A1 (ru)	2021-04-07
LT3805220T (lt)	2024-08-26
US12139489B2 (en)	2024-11-12
MY198568A (en)	2023-09-05
DK3805220T3 (da)	2024-08-26
AR115455A1 (es)	2021-01-20
IL279051B2 (en)	2025-01-01
AU2019277548B2 (en)	2023-12-14
US20240352015A1 (en)	2024-10-24
PT3805220T (pt)	2024-08-16
FI3805220T3 (fi)	2024-08-30
US20210122751A1 (en)	2021-04-29
CL2020003002A1 (es)	2021-04-16
UA129229C2 (uk)	2025-02-19

Publication	Publication Date	Title
EP3690038A4 (fr)	2021-05-19	Conjugué anticorps-dérivé de pyrrolobenzodiazépine
MA52795A (fr)	2021-04-14	Dérivé de carbamoylpyridone polycyclique
EP3555124C0 (fr)	2024-05-01	Tcr nyeso
DK3810587T3 (da)	2022-10-31	Substituerede alkoxypyridinylindolsulfonamider
DK4067344T3 (da)	2026-01-12	Cycloalkylurinstofderivat
MA52802A (fr)	2021-04-14	Dérivé de pyridone polycyclique
LT3830085T (lt)	2024-02-12	Deuterinti lanifibranoro dariniai
EP3781060A4 (fr)	2022-01-26	Cryosonde
EP3645897A4 (fr)	2021-02-17	Monture
DK3768669T3 (da)	2023-04-24	Piperazinazaspiroderivater
PT4039675T (pt)	2024-09-16	Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3784463A4 (fr)	2022-01-19	Fluorosulfones
PL3655420T3 (pl)	2026-02-16	Chromatografia
EP3885347A4 (fr)	2022-11-16	Dérivé de dihydropyrrolopyrazole
DK3823970T3 (da)	2024-02-05	Yderligere substituerede triazoloquinoxalinderivater
EP3745904C0 (fr)	2024-08-21	Poignée de bâton
DK3823971T3 (da)	2022-09-05	Substituerede triazol-quinoxalin-derivater
EP3721129A4 (fr)	2021-09-08	Cryosphère
EP3831810A4 (fr)	2022-04-20	Dérivé de benzène
PT3796975T (pt)	2023-11-15	Derivados de sulfonilaminobenzamida
EP3590944A4 (fr)	2020-12-09	Dérivé d'azétidine
DK3894410T3 (da)	2023-11-27	Substituerede xanthinderivater
EP3770162A4 (fr)	2021-12-01	Dérivé de dihydrochromène
DK3587968T3 (da)	2022-02-21	Fluidsystem
EP3741757A4 (fr)	2021-11-03	Dérivé de dihydro-indolizinone